Anke Hemmerling, MD, PhD, MPH
Associate Professor
Campuswide Accounting
Chancellor/EVC/FAS

She received her medical and public health training at the Humboldt University in Berlin (Germany) and at the University of California, Berkeley (UCB). During her clinical training, she repeatedly worked in health projects and hospitals in Latin America.

Always with a focus on global women’s health, her early career research covered medication abortion, infertility and fertility choices, and safe motherhood. Her current clinical research is focusing on the prevention of HIV and other genital infections such as bacterial vaginosis in women, conducting a number of clinical trials in the US and South Africa. She served as the protocol co-Chair of the NIH-sponsored multi-site phase 2B study for the prevention of bacterial vaginosis using the live biotherapeutic product LACTIN-V.

At UC San Francisco and UC Berkeley, she is mentoring and teaching several courses for medical students, undergraduate and graduate students, as well as post-doctoral students in several educational programs.

Dr. Hemmerling serves as a senior technical adviser for the Initiative for Multipurpose Prevention Technologies for Reproductive Health (IMPT) and on several data safety monitoring boards for federally funded clinical studies. In addition, she is a member of the Education Committee at the UCGHI Center of Expertise in Women’s Health, Gender and Empowerment.

Areas of Interest:

• Prevention of sexually transmitted infections (STI)
• Drug development: Microbicides and live biotherapeutic products to prevent HIV/STI
• Fertility Choices
• Safe Motherhood

• Connecting the Dots: Translating the Vaginal Microbiome Into a Drug.
  The Journal of infectious diseases 2021 Lagenaur LA, Hemmerling A, Chiu C, Miller S, Lee PP, Cohen CR, Parks TP
• Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. Reply.
  The New England journal of medicine 2020 Cohen CR, Parks T, Hemmerling A
• Bridging the gap: advancing multipurpose prevention technologies from the lab into the hands of women†.
  Biology of reproduction 2020 Young Holt B, Kiarie J, Kopf GS, Nanda K, Hemmerling A, Achilles SL
• Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: strategic insights from key stakeholders†.
  Biology of reproduction 2020 Hemmerling A, Christopher E, Young Holt B
• Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
  The New England journal of medicine 2020 Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, Green L, Miller S, Powell J, Parks T, Hemmerling A
• Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus.
  The Journal of rheumatology 2019 Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ
• A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV.
  The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 2018 Young Holt B, Dellplain L, Creinin MD, Peine KJ, Romano J, Hemmerling A
• Nutrition Education in Internal Medicine Residency Programs and Predictors of Residents' Dietary Counseling Practices.
  Journal of medical education and curricular development 2018 Khandelwal S, Zemore SE, Hemmerling A
• Emerging Technologies to Prevent Pregnancy and Sexually Transmitted Infections in Women.
  Seminars in reproductive medicine 2016 Seidman D, Hemmerling A, Smith-McCune K
• Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach.
  BJOG : an international journal of obstetrics and gynaecology 2014 Young Holt B, Romano J, Manning J, Hemmerling A, Shields W, Vyda L, Lusti-Narasimhan M
• Prioritizing multipurpose prevention technology development and investments using a target product profile.
  Antiviral research 2013 Romano J, Manning J, Hemmerling A, McGrory E, Holt BY
• Developing multipurpose reproductive health technologies: an integrated strategy.
  AIDS research and treatment 2013 Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B
• Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations.
  Sexually transmitted diseases 2012 Hemmerling A, Harrison WG, Brown JM, Moscicki B, Oziemkowska M, Bukusi EA, Cohen CR
• Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05.
  Sexually transmitted diseases 2011 Ngugi BM, Hemmerling A, Bukusi EA, Kikuvi G, Gikunju J, Shiboski S, Fredricks DN, Cohen CR
• Probiotics: the potential for a live microbicide to prevent HIV.
  Journal of acquired immune deficiency syndromes (1999) 2011 Hemmerling A, Cohen CR
• Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis.
  Sexually transmitted diseases 2010 Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Foster-Rosales A, Cohen CR
• Women front and center: the opportunities of involving women in participatory health research worldwide.
  Journal of women's health (2002) 2010 Decker M, Hemmerling A, Lankoande F
• Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis.
  Sexually transmitted diseases 2009 Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Cohen CR
• Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally.
  Journal of women's health (2002) 2007 Hemmerling A, Potts M, Walsh J, Young-Holt B, Whaley K, Stefanski DA
• The safety of misoprostol.
  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2006 Hemmerling A
• The worldwide burden of postpartum haemorrhage: Policy development where inaction is lethal.
  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2006 Potts M, Hemmerling A
• Misoprostol and declining abortion-related morbidity in Santo Domingo, Dominican Republic: a temporal association.
  BJOG : an international journal of obstetrics and gynaecology 2005 Miller S, Lehman T, Campbell M, Hemmerling A, Anderson SB, Rodriguez H, Gonzalez WV, Cordero M, Calderon V
• Emotional impact and acceptability of medical abortion with mifepristone: a German experience.
  Journal of psychosomatic obstetrics and gynaecology 2005 Hemmerling A, Siedentopf F, Kentenich H
• Couples becoming parents: something special after IVF?
  Journal of psychosomatic obstetrics and gynaecology 2004 Ulrich D, Gagel DE, Hemmerling A, Pastor VS, Kentenich H
• Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency.
  Clinical nephrology 1996 Haubitz M, Ehlerding G, Beigel A, Heuer U, Hemmerling AE, Thoma HA
• Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products.
  The Clinical investigator 1994 Wagner D, Wagenbreth I, Stachan-Kunstyr R, Thoma HA, Hemmerling AE, Flik J